The Ultimate Directory on Healthcare Webinars

Join us for a cutting-edge webinar delving into innovative clinical approaches and endpoints for new glaucoma treatments. Today, intraocular pressure (IOP) lowering therapies are currently the only proven neuroprotective therapies for glaucoma. While IOP therapies and devices are highly prevalent in use, unfortunately even with these treatments up to one in four patients still experience blindness in at least one eye. With disease progression still often significant despite the application of these therapies, clearly, this is an area of opportunity for new therapeutic entries. As companies explore new therapies to provide neuroprotection (preserving neuronal integrity) or even neuroenhancement (improving neuronal function), finding the right clinical approaches and endpoints to prove efficacy is of utmost importance. This webinar, featuring leading glaucoma expert and Ora Chief Medical Officer, Dr. Gustavo De Moraes, highlights ground-breaking designs and endpoints for new glaucoma therapies that help better measure therapeutic impact and even demonstrate IOP-independent neuroprotection. Hear an overview of the latest research in this field, understand considerations for programs including currently stated FDA opinions, and dive deeply into recent studies that show the viability of these novel endpoints to demonstrate efficacy for new glaucoma potential therapies. Ora Inc. is the only ophthalmic clinical trials company with a research and development (R&D) department focused on the evolution of clinical trials. As one of the top glaucoma experts in the world, Dr. De Moraes leads the Ora R&D team in exploring and developing new endpoints. He is excited to share with attendees the latest research shaping the future of glaucoma clinical trials, and to provide considerations for their therapeutic program to optimally capture the efficiency benefits for these challenging patients.

Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification. BsAbs have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer, chronic inflammatory diseases, autoimmunity, neurodegeneration, bleeding disorders and infections. Currently, there are 12 bispecific antibodies approved worldwide. Natural antibodies are monospecific, while BsAbs recognize two different epitopes or antigens. This makes BsAbs hold great therapeutic promise for many diseases by linking an effector to a target cell, acting as ligands to two receptors or other mechanisms. However, the translation of these concepts into treatments is challenging. Without proper engineering, the side products from the light chain mispairing, heavy chain mispairing and BsAb fragments could lead to low purity, inability of repetition and toxicity. To solve the technical problems, advanced design strategies have been investigated, such as Knobs-into-holes, CrossMab technology, Duobody and common light chain. These technologies have greatly improved the development of bispecific antibodies, with many entities employing similar design approaches to develop their BsAb therapeutics. Do BsAb designs always work well as reported? What considerations should be taken for BsAb design? GenScript has production experience on thousands of BsAbs including about 80 BsAb formats and know well how the design affects the production. This webinar will focus on various strategies for BsAb design, the side products and how to get high purity BsAbs with different purification columns. Join this webinar to gain insights into the diverse applications, design considerations and production strategies of bispecific antibodies.

Chronic underfunding, rising deferral and mounting operational constraints have led to a declining Net Asset Value (NAV) in most healthcare facilities. Join us for this trailblazing webinar to explore the implications of emerging facilities risk and how to ensure compatibility between facilities and clinical priorities to support, stabilize, and improve your portfolio’s NAV.

A-TEEM (Absorbance-Transmittance Excitation Emission Matrix) is a spectroscopic technique that can be used to evaluate and fingerprint complex mixtures. This webinar will discuss the A-TEEM compliance package for GMP labs, including the Aqualog A-TEEM spectrometer, IQ/OQ documentation and procedures, EzPAT OPC UA Server for PAT Software control of A-TEEM acquisitions, and A-TEEM Direktor multivariate analysis software with A-TEEM specific guided workflow. Key learning objectives include understanding compliance solutions for A-TEEM acquisitions and data analysis, as well as how A-TEEM is used in GMP Labs for pharmaceutical analysis.

Almost everything we've ever achieved has been done by groups working together: our naturally social, interconnected brains are designed to function best collectively. Technology helps us to share our wisdom and knowledge much more diversely than ever before. We sit down with neuroscientist and best-selling author Dr Hannah Critchlow to explore in what ways collective intelligence might be applied through alumni networks.

Lisa Roberson, RDN, LD Learning Objectives: 1. Outline key challenges of the Food as Medicine movement, including food insecurity and social determinants of health 2. Compare and contrast various medically tailored nutrition strategies 3. Identify possible solutions that are available to mitigate Food as Medicine implementation challenges

Clinical research often lacks sufficient evidence, leading to prescribing decisions in healthcare that are not evidence-based or supported by randomized, double-blind clinical trials. This webinar will discuss how combining a unified clinical trial data collection platform with intelligent automation can revolutionize drug development and why the current status quo is no longer sufficient.

Hepatitis B carries a significant burden across the African continent with over 60 million Africans living with hepatitis B. To improve testing, access to management and treatment, and prevention it takes significant political commitment and advocacy. This webinar will discuss strategies to engage with political leaders within the African context. We hope by the end of this session you will be inspired and encouraged to create similar initiatives in your communities.

Since 2017, the FDA’s Oncology Center of Excellence (OCE) has created more than 300 research and educational outreach projects and programs focused on advancing the design, analysis, and regulations surrounding oncology drug development. In this webinar, Worldwide Clinical Trials’ clinical research methodology and oncology strategy experts will present the OCE’s most imperative initiatives.

Learn how Tellmi and First Steps ED have been collaborating to support young people with disordered eating, creating a clear support pathway